```
********************************
FILE 'USPAT' ENTERED AT 10:59:43 ON 30 MAR 1999

 ********************************
 *      WELCOME TO THE          *
 *   U.S. PATENT TEXT FILE      *
 ********************************

=> set plurals on perm

SET COMMAND COMPLETED

=> file uspat usocr jpo epo

FILE 'USPAT' ENTERED AT 11:00:12 ON 30 MAR 1999

 ********************************
 *      WELCOME TO THE          *
 *   U.S. PATENT TEXT FILE      *
 ********************************

     'USOCR' ENTERED AT 11:00:12 ON 30 MAR 1999

FILE 'JPO' ENTERED AT 11:00:12 ON 30 MAR 1999

 ********************************
 *          G P I               *
 *  JAPANESE PATENT ABSTRACTS   *
 *                              *
 *  THE FILE IS CURRENT THROUGH OCTOBER 31, 1998.      *
 ********************************


FILE 'EPO' ENTERED AT 11:00:12 ON 30 MAR 1999

 ********************************
 *          G P I               *
 *  EUROPEAN PATENT ABSTRACTS   *
 ********************************


=> s fc.epsilon.(3a)high(w)affinity

FILE 'USPAT'
      16795 FC
       4754 FCS
      20784 FC
            (FC OR FCS)
      42509 EPSILON
          5 EPSILONS
      42509 EPSILON
            (EPSILON OR EPSILONS)
        115 FC.EPSILON.
            (FC(W)EPSILON)
    1445155 HIGH
       1308 HIGHS
    1445202 HIGH
            (HIGH OR HIGHS)
      46167 AFFINITY
       4092 AFFINITIES
      46962 AFFINITY
            (AFFINITY OR AFFINITIES)
L1        1 FC.EPSILON.(3A)HIGH(W)AFFINITY

FILE 'USOCR'
       1473 FC
         54 FCS
       1511 FC
            (FC OR FCS)
        383 EPSILON
          0 FC.EPSILON.
            (FC(W)EPSILON)
      79249 HIGH
         17 HIGHS
      79250 HIGH
            (HIGH OR HIGHS)
       1596 AFFINITY
         54 AFFINITIES
       1622 AFFINITY
            (AFFINITY OR AFFINITIES)
L2        0 FC.EPSILON.(3A)HIGH(W)AFFINITY

FILE 'JPO'
       2548 FC
        229 FCS
       2768 FC
            (FC OR FCS)
        230 EPSILON
          1 FC.EPSILON.
            (FC(W)EPSILON)
    1013820 HIGH
         57 HIGHS
    1013846 HIGH
            (HIGH OR HIGHS)
       5870 AFFINITY
         70 AFFINITIES
       5920 AFFINITY
            (AFFINITY OR AFFINITIES)
L3        0 FC.EPSILON.(3A)HIGH(W)AFFINITY

FILE 'EPO'
        698 FC
         32 FCS
        730 FC
            (FC OR FCS)
       1610 EPSILON
         27 FC.EPSILON.
            (FC(W)EPSILON)
     266194 HIGH
         24 HIGHS
     266206 HIGH
            (HIGH OR HIGHS)
       3847 AFFINITY
         89 AFFINITIES
       3910 AFFINITY
            (AFFINITY OR AFFINITIES)
L4        0 FC.EPSILON.(3A)HIGH(W)AFFINITY

TOTAL FOR ALL FILES
L5        1 FC.EPSILON.(3A) HIGH(W) AFFINITY

=> d l5 leg ab


US PAT NO:    5,837,242 [IMAGE AVAILABLE]          L5: 1 of 1
DATE ISSUED:  Nov. 17, 1998
TITLE:        Multivalent and multispecific binding proteins, their
              manufacture and use
INVENTOR:     Kaspar-Philipp Holliger, Cambridge, United Kingdom
              Andrew David Griffiths, Cambridge, United Kingdom
              Hendricus Renerus Jacobus Matheus Hoogenboom, Hasselt,
               Belgium
              Magnus Malmqvist, Upsala, Sweden
              James David Marks, Kensington, CA
              Brian Timothy McGuinness, Cambridge, United Kingdom
              Anthony Richard Pope, Cambridge, United Kingdom
              Terence Derek Prospero, Cambridge, United Kingdom
              Gregory Paul Winter, Cambridge, United Kingdom
ASSIGNEE:     Medical Research Council, London, England (foreign corp.)
              Cambridge Antibody Technology Limited, Melbourn, England
               (foreign corp.)
APPL-NO:      08/448,418
DATE FILED:   May 14, 1996
ART-UNIT:     166
PRIM-EXMR:    Stephen Walsh
ASST-EXMR:    Karen E. Brown
LEGAL-REP:    Marshall, O'Toole, Gerstein, Murray & Borun

US PAT NO:    5,837,242 [IMAGE AVAILABLE]          L5: 1 of 1

ABSTRACT:

 Polypeptides comprising a first domain, which comprises a binding region
of an immunoglobulin heavy chain variable region, and a second domain,
which comprises a binding region of an immunoglobulin light chain
variable region, the domains being linked but incapable of associating
with each other to form an antigen binding site, associate to form
antigen binding multimers, such as dimers, which may be multivalent or
have multispecificity. The domains may be linked by a short peptide
linker or may be joined directly together. Bispecific dimers may have
longer linkers. Methods of preparation of the polypeptides and multimers
and diverse repertoires thereof, and their display on the surface of
bacteriophage for easy selection of binders of interest, are disclosed,
along with many utilities.

=>  s fc.epsilon.(3a)high(w)affinity or fc.epsilon.ri

FILE 'USPAT'
      16795 FC
       4754 FCS
      20784 FC
            (FC OR FCS)
      42509 EPSILON
          5 EPSILONS
      42509 EPSILON
            (EPSILON OR EPSILONS)
        115 FC.EPSILON.
            (FC(W)EPSILON)
    1445155 HIGH
       1308 HIGHS
    1445202 HIGH
            (HIGH OR HIGHS)
      46167 AFFINITY
       4092 AFFINITIES
      46962 AFFINITY
            (AFFINITY OR AFFINITIES)
          1 FC.EPSILON.(3A)HIGH(W)AFFINITY
      16795 FC
       4754 FCS
      20784 FC
            (FC OR FCS)
      42509 EPSILON
          5 EPSILONS
      42509 EPSILON
            (EPSILON OR EPSILONS)
      10106 RI
        707 RIS
      10736 RI
            (RI OR RIS)
         36 FC.EPSILON.RI
            (FC(W)EPSILON(W)RI)
L6       36 FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI

FILE 'USOCR'
       1473 FC
         54 FCS
       1511 FC
            (FC OR FCS)
        383 EPSILON
          0 FC.EPSILON.
            (FC(W)EPSILON)
      79249 HIGH
         17 HIGHS
      79250 HIGH
            (HIGH OR HIGHS)
       1596 AFFINITY
         54 AFFINITIES
       1622 AFFINITY
            (AFFINITY OR AFFINITIES)
          0 FC.EPSILON.(3A)HIGH(W)AFFINITY
       1473 FC
         54 FCS
       1511 FC
            (FC OR FCS)
```

```
      383 EPSILON
     4093 RI
      467 RIS
     4483 RI
          (RI OR RIS)
        0 FC.EPSILON.RI
          (FC(W)EPSILON(W)RI)
L7      0 FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI

FILE 'JPO'
     2548 FC
      229 FCS
     2768 FC
          (FC OR FCS)
      230 EPSILON
        1 FC.EPSILON.
          (FC(W)EPSILON)
  1013820 HIGH
       57 HIGHS
  1013846 HIGH
          (HIGH OR HIGHS)
     5870 AFFINITY
       70 AFFINITIES
     5920 AFFINITY
          (AFFINITY OR AFFINITIES)
        0 FC.EPSILON.(3A)HIGH(W)AFFINITY
     2548 FC
      229 FCS
     2768 FC
          (FC OR FCS)
      230 EPSILON
     1476 RI
       46 RIS
     1519 RI
          (RI OR RIS)
        1 FC.EPSILON.RI
          (FC(W)EPSILON(W)RI)
L8      1 FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI

FILE 'EPO'
      698 FC
       32 FCS
      730 FC
          (FC OR FCS)
     1610 EPSILON
       27 FC.EPSILON.
          (FC(W)EPSILON)
   266194 HIGH
       24 HIGHS
   266206 HIGH
          (HIGH OR HIGHS)
     3847 AFFINITY
       89 AFFINITIES
     3910 AFFINITY
          (AFFINITY OR AFFINITIES)
        0 FC.EPSILON.(3A)HIGH(W)AFFINITY
      698 FC
       32 FCS
      730 FC
          (FC OR FCS)
     1610 EPSILON
      543 RI
       48 RIS
      585 RI
          (RI OR RIS)
        4 FC.EPSILON.RI
          (FC(W)EPSILON(W)RI)
L9      4 FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI

TOTAL FOR ALL FILES
L10    41 FC.EPSILON.(3A) HIGH(W) AFFINITY OR FC.EPSILON.RI

=> d l10 1-41 leg ab
```

US PAT NO: 5,877,396 [IMAGE AVAILABLE] L10: 1 of 41
DATE ISSUED: Mar. 2, 1999
TITLE: Mice mutant for functional Fc receptors and method of treating autoimmune diseases
INVENTOR: Jeffrey V. Ravetch, New York, NY
Toshiyuki Takai, Okayama, Japan
Diana Sylvestre, New York, NY
Raphael Clynes, New York, NY
ASSIGNEE: Sloan Kettering Institute for Cancer Research, New York, NY (U.S. corp.)
APPL-NO: 08/292,569
DATE FILED: Aug. 18, 1994
ART-UNIT: 189
PRIM-EXMR: Brian R. Stanton
LEGAL-REP: John P. White

US PAT NO: 5,877,396 [IMAGE AVAILABLE] L10: 1 of 41

ABSTRACT:
Disclosed herein is a non-naturally occurring non-human vertebrate animal incapable of expressing a functional Fc receptor which may optionally be capable of expressing a protein which comprises a domain of a human Fc receptor, as well as DNA encoding such Fc receptor-based proteins. Also disclosed are in vivo methods for identifying proinflammatory agents that depend on a functional Fc receptor, in vivo methods for identifying proinflammatory agents that do not depend on a functional Fc receptor, and both in vivo and in vitro methods of identifying anti-inflammatory agents. Pharmaceutical compositions containing, and methods of treating inflammation with anti-inflammatory agents are also described.

US PAT NO: 5,874,404 [IMAGE AVAILABLE] L10: 2 of 41
DATE ISSUED: Feb. 23, 1999
TITLE: Immunoglobulin E receptor .alpha.-chain inhibits IgE production and secondary allergic responses
INVENTOR: Chisei Ra, 14-13, Hanazono 2-chome, Hanamigawa-ku, Chiba-shi, Chiba, Japan
Koji Naito, Osaka, Japan
Minoru Hirama, Osaka, Japan
Ko Okumura, Chiba, Japan
Yukiyoshi Yanagihara, Tokyo, Japan
ASSIGNEE: Chisei Ra, Chiba, Japan (foreign indiv.)
The Green Cross Corporation, Osaka, Japan (foreign corp.)
APPL-NO: 08/238,027
DATE FILED: May 3, 1994
ART-UNIT: 162
PRIM-EXMR: Deborah Crouch
ASST-EXMR: Anne Marie S. Beckerleg
LEGAL-REP: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC

US PAT NO: 5,874,404 [IMAGE AVAILABLE] L10: 2 of 41

ABSTRACT:
Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha.-chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha.-chain. The composition is clinically useful for blocking allergic responses. An animal model for use in the screening of prophylactic and therapeutic compositions for IgE-related diseases is also disclosed.

US PAT NO: 5,874,268 [IMAGE AVAILABLE] L10: 3 of 41
DATE ISSUED: Feb. 23, 1999
TITLE: Method of introducing exogenous compounds into cells by electroporation and apparatus for same
INVENTOR: Tobias Meyer, Durham, NC
ASSIGNEE: Duke University, Durham, NC (U.S. corp.)
APPL-NO: 08/718,658
DATE FILED: Sep. 23, 1996
ART-UNIT: 188
PRIM-EXMR: Jon P. Weber
LEGAL-REP: Myers Bigel Sibley & Sajovec

US PAT NO: 5,874,268 [IMAGE AVAILABLE] L10: 3 of 41

ABSTRACT:
An electroporation apparatus for introducing exogenous material into cells is described herein. The apparatus comprises first a base member (15) configured for holding a cell support, the cell support having a top surface portion, with the top surface portion configured for carrying adherent cells. The apparatus further comprises an electrode carrier (25) operably associated with the base member, the electrode carrier having a bottom surface portion, a first electrode (30) connected to the electrode carrier, and a second electrode (35) also connected to the electrode carrier. The electrode carrier has a channel (40) formed therein, with the channel positioned between the first electrode and the second electrode, so that exogenous material may be introduced through the channel and into contact with the cells. Methods for introducing exogenous compounds into a cell and for visually detecting the location of binding events within a cell are also disclosed.

US PAT NO: 5,872,223 [IMAGE AVAILABLE] L10: 4 of 41
DATE ISSUED: Feb. 16, 1999
TITLE: Immunoconjugates comprising tyrosine kinase inhibitors
INVENTOR: Fatih M. Uckun, White Bear Lake, MN
ASSIGNEE: Regents of the University of Minnesota, Minneapolis, MN (U.S. corp.)
APPL-NO: 08/755,462
DATE FILED: Nov. 22, 1996
ART-UNIT: 162
PRIM-EXMR: Lila Feisee
ASST-EXMR: Susan Ungar
LEGAL-REP: Merchant, Gould, Smith, Edell & Welter

US PAT NO: 5,872,223 [IMAGE AVAILABLE] L10: 4 of 41

ABSTRACT:
Immunoconjugates effective for treating cancers and autoimmune diseases in humans are provided which comprise a tyrosine kinase inhibitor linked to a ligand targeting a cell surface receptor which are specifically capable of inhibiting receptor associated tyrosine kinases.

US PAT NO: 5,859,314 [IMAGE AVAILABLE] L10: 5 of 41
DATE ISSUED: Jan. 12, 1999
TITLE: Mice with targeted tyrosine kinase, lyn, disruption
INVENTOR: Margaret L. Hibbs, Parkville, Australia
Ashley R. Dunn, Parkville, Australia
Dianne Graill, Parkville, Australia
George Hodgson, Parkville, Australia
David M. Tarlington, Parkville, Australia
Jane Armes, Heidelberg, Australia
ASSIGNEE: Ludwig Institute for Cancer Research, New York, NY (U.S. corp.)
APPL-NO: 08/730,876
DATE FILED: Oct. 18, 1996
ART-UNIT: 184
PRIM-EXMR: Jasemine C. Chambers
ASST-EXMR: Deborah J. R. Clark
LEGAL-REP: Felfe & Lynch

US PAT NO: 5,859,314 [IMAGE AVAILABLE] L10: 5 of 41

ABSTRACT:
A non-human animal carrying a disruption of a gene encoding a lyn protein tyrosine kinase provides a convenient system for the study of diseases associated with or caused by lyn deficiency, and for the testing of therapeutic agents for the treatment or prevention of diseases which include autoimmune diseases, allergy, asthma and malignant disease.

US PAT NO: 5,859,017 [IMAGE AVAILABLE] L10: 6 of 41
DATE ISSUED: Jan. 12, 1999
TITLE: Method for inhibiting mast cell and basophil activation
INVENTOR: Elisa Eiseman, Seattle, WA
Emer Clarke, Seattle, WA

Jack W. Singer, Seattle, WA
Stuart L. Bursten, Snoqualmie, WA
ASSIGNEE: Cell Therapeutics, Inc., Seattle, WA (U.S. corp.)
APPL-NO: 08/221,814
DATE FILED: Apr. 1, 1994
ART-UNIT: 129
PRIM-EXMR: Deborah Lambkin
LEGAL-REP: Stephen Faciszewski

US PAT NO: 5,859,017 [IMAGE AVAILABLE] L10: 6 of 41

ABSTRACT:
In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.

US PAT NO: 5,859,000 [IMAGE AVAILABLE] L10: 7 of 41
DATE ISSUED: Jan. 12, 1999
TITLE: Method for reducing mast cell mediated allergic reactions
INVENTOR: Tad Dowell, Salt Lake City, UT
Steven D. Norton, Salt Lake City, UT
Barbara A. Araneo, Salt Lake City, UT
ASSIGNEE: University of Utah Research Foundation, Salt Lake City, UT (U.S. corp.)
Pharmadigm, Inc., Salt Lake City, UT (U.S. corp.)
APPL-NO: 08/966,385
DATE FILED: Nov. 7, 1997
ART-UNIT: 164
PRIM-EXMR: Raymond J. Henley, III
LEGAL-REP: Rothwell, Figg, Ernst & Kurz, P.C.

US PAT NO: 5,859,000 [IMAGE AVAILABLE] L10: 7 of 41

ABSTRACT:
The present invention is directed to a method for reducing mast cell mediated allergic reactions, including mast cell mediated allergy and asthma. Mast cell mediated allergic reactions, including type I hypersensitivity reasponse to allergens and asthma, are reduced by administering a dehydroepiandrosterone (DHEA) derivative to a patient in a manner which quickly raises blood levels of the active agent.

US PAT NO: 5,858,981 [IMAGE AVAILABLE] L10: 8 of 41
DATE ISSUED: Jan. 12, 1999
TITLE: Method of inhibiting phagocytosis
INVENTOR: Alan D. Schreiber, Philadelphia, PA
Jong-Gu Park, Drexel Hill, PA
ASSIGNEE: University of Pennsylvania, Philadelphia, PA (U.S. corp.)
APPL-NO: 08/657,884
DATE FILED: Jun. 7, 1996
ART-UNIT: 164
PRIM-EXMR: David Saunders
ASST-EXMR: F. Pierre VanderVegt
LEGAL-REP: Nixon & Vanderhye P.C.

US PAT NO: 5,858,981 [IMAGE AVAILABLE] L10: 8 of 41

ABSTRACT:
The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.

US PAT NO: 5,856,180 [IMAGE AVAILABLE] L10: 9 of 41
DATE ISSUED: Jan. 5, 1999
TITLE: Immortalization of dendritic cells with V-MYC oncogene
INVENTOR: Francesca Granucci, Milan, Italy
ASSIGNEE: BIOTOP s.a.s. di Rita Cassarin, Milan, Italy (foreign corp.)
APPL-NO: 08/549,666
DATE FILED: Nov. 29, 1995
ART-UNIT: 162
PRIM-EXMR: Jasemine C. Chambers
ASST-EXMR: Karen M. Hauda
LEGAL-REP: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

US PAT NO: 5,856,180 [IMAGE AVAILABLE] L10: 9 of 41

ABSTRACT:

The present invention refers to immortalized dendritic cells, to a process for their production from primary cultures and to their use for the activation, in vivo or in vitro, of T lymphocytes in antigen specific way.

US PAT NO: 5,851,828 [IMAGE AVAILABLE] L10: 10 of 41
DATE ISSUED: Dec. 22, 1998
TITLE: Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
INVENTOR: Brian Seed, Boston, MA
Babak Banapour, Boston, MA
Charles Romeo, Belmont, MA
Waldemar Kolanus, Watertown, MA
ASSIGNEE: The General Hospital Corporation, Boston, MA (U.S. corp.)
APPL-NO: 08/284,391
DATE FILED: Aug. 2, 1994
ART-UNIT: 168
PRIM-EXMR: Robert D. Budens
LEGAL-REP: Clark & Elbing LLP

US PAT NO: 5,851,828 [IMAGE AVAILABLE] L10: 10 of 41

ABSTRACT:
Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.

US PAT NO: 5,851,786 [IMAGE AVAILABLE] L10: 11 of 41
DATE ISSUED: Dec. 22, 1998
TITLE: Product and process to regulate actin polymerization
INVENTOR: Gary L. Johnson, Boulder, CO
ASSIGNEE: National Jewish Center For Immunology and Respiratory Medicine, Denver, CO (U.S. corp.)
APPL-NO: 08/534,694
DATE FILED: Sep. 27, 1995
ART-UNIT: 121
PRIM-EXMR: Louise Leary
LEGAL-REP: Giulio A. DeConti, Jr., Catherine J. Kara

US PAT NO: 5,851,786 [IMAGE AVAILABLE] L10: 11 of 41

ABSTRACT:
The present invention relates to methods useful for identifying compounds capable of specifically regulating actin polymerization, stress fiber formation or focal adhesion assembly by regulating G.sub..alpha.12 and/or G.sub..alpha.13 activity in cells involved in inflammatory responses, immune responses, allergic responses and neuronal responses, kits to perform such assays and methods to control disease related to such responses.

US PAT NO: 5,843,728 [IMAGE AVAILABLE] L10: 12 of 41
DATE ISSUED: Dec. 1, 1998
TITLE: Redirection of cellular immunity by receptor chimeras
INVENTOR: Brian Seed, Boston, MA
Charles Romeo, Belmont, MA
Waldemar Kolanus, Watertown, MA
ASSIGNEE: The General Hospital Corporation, Boston, MA (U.S. corp.)
APPL-NO: 08/417,495
DATE FILED: Apr. 5, 1995
ART-UNIT: 162
PRIM-EXMR: Karen Cochrane Carlson
LEGAL-REP: Clark & Elbing LLP

US PAT NO: 5,843,728 [IMAGE AVAILABLE] L10: 12 of 41

ABSTRACT:
Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

US PAT NO: 5,843,672 [IMAGE AVAILABLE] L10: 13 of 41
DATE ISSUED: Dec. 1, 1998
TITLE: Allergenic proteins and peptides from dog dander and uses therefor
INVENTOR: Jay P. Morgenstern, Boston, MA
Andrzej Konieczny, Belmont, MA
Christine B. Bizinkauskas, Dorchester, MA
Andrew W. Brauer, Salem, MA
ASSIGNEE: ImmuLogic Pharmaceutical Corporation, Waltham, MA (U.S. corp.)
APPL-NO: 08/467,603
DATE FILED: Jun. 6, 1995
ART-UNIT: 184
PRIM-EXMR: Eric Grimes
LEGAL-REP: Elizabeth A. Hanley, Amy E.Lahive & Cockfield, LLP
Mandragouras

US PAT NO: 5,843,672 [IMAGE AVAILABLE] L10: 13 of 41

ABSTRACT:
Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.

US PAT NO: 5,837,243 [IMAGE AVAILABLE] L10: 14 of 41
DATE ISSUED: Nov. 17, 1998
TITLE: Therapeutic compounds comprised of anti-Fc receptor antibodies
INVENTOR: Yashwant M. Deo, Audubon, PA
Joel Goldstein, Edison, NJ
Robert Graziano, Frenchtown, NJ
Chezian Somasundaram, Allentown, PA
ASSIGNEE: Medarex, Inc., Annandale, NJ (U.S. corp.)
APPL-NO: 08/661,052
DATE FILED: Jun. 7, 1996
ART-UNIT: 162
PRIM-EXMR: Lila Feisee
ASST-EXMR: Geetha Bansal
LEGAL-REP: Lahive & Cockfield, LLP

US PAT NO: 5,837,243 [IMAGE AVAILABLE] L10: 14 of 41

ABSTRACT:

Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.

US PAT NO: 5,837,242 [IMAGE AVAILABLE] L10: 15 of 41
DATE ISSUED: Nov. 17, 1998
TITLE: Multivalent and multispecific binding proteins, their manufacture and use
INVENTOR: Kaspar-Philipp Holliger, Cambridge, United Kingdom
Andrew David Griffiths, Cambridge, United Kingdom
Hendricus Renerus Jacobus Matheus Hoogenboom, Hasselt, Belgium
Magnus Malmqvist, Upsala, Sweden
James David Marks, Kensington, CA
Brian Timothy McGuinness, Cambridge, United Kingdom
Anthony Richard Pope, Cambridge, United Kingdom
Terence Derek Prospero, Cambridge, United Kingdom
Gregory Paul Winter, Cambridge, United Kingdom
ASSIGNEE: Medical Research Council, London, England (foreign corp.)
Cambridge Antibody Technology Limited, Melbourn, England (foreign corp.)
APPL-NO: 08/448,418
DATE FILED: May 14, 1996
ART-UNIT: 166
PRIM-EXMR: Stephen Walsh
ASST-EXMR: Karen E. Brown
LEGAL-REP: Marshall, O'Toole, Gerstein, Murray & Borun

US PAT NO: 5,837,242 [IMAGE AVAILABLE] L10: 15 of 41

ABSTRACT:

Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.

US PAT NO: 5,824,487 [IMAGE AVAILABLE] L10: 16 of 41
DATE ISSUED: Oct. 20, 1998
TITLE: Method for screening for targets for anti-inflammatory or anti-allergic agents
INVENTOR: Jeffrey V. Ravetch, New York, NY
Tomohiro Kurosaki, Fort Lee, NJ
ASSIGNEE: Sloan-Kettering Institute for Cancer Research, New York, NY (U.S. corp.)
APPL-NO: 08/542,686
DATE FILED: Oct. 13, 1995
ART-UNIT: 186
PRIM-EXMR: Ronald B. Schwadron
LEGAL-REP: John P. White

US PAT NO: 5,824,487 [IMAGE AVAILABLE] L10: 16 of 41

ABSTRACT:
This invention provides a method for identifying a cellular protein capable of specifically binding to an activated antibody receptor, whose cytoplasmic domain comprising an ARH1 motif, comprising (a) obtaining cells comprising receptors having the ARH1 motif; (b) lysing the cells under conditions whereby the native complex of the receptor having the ARH1 motif and the cellular protein is preserved;(c) isolating the complex; and (d) testing the associated receptor and the protein for biochemical activities, thereby identifying the cellular protein capable of specifically binding to an activated antibody receptor, whose cytoplasmic domain comprising an ARH1 motif. This invention further provides a method for identifying a cellular molecule capable of being a target for designing drugs for autoimmune disease, inflammation or allergy which comprises (a) contacting a cell lysate with a molecule having a motif of amino acid sequence, AENTITYSLLKHP under the conditions permitting formation of a complex between the cellular target molecule with the motif; (b) isolating the complex formed in step (a); and (c) testing the complex for biochemical activities, thereby identifying the cellular molecule capable of being a target for designing drugs for autoimmune disease, inflammation or allergy.

US PAT NO: 5,807,988 [IMAGE AVAILABLE] L10: 17 of 41
DATE ISSUED: Sep. 15, 1998
TITLE: Isolation, characterization, and use of the human and subunit of the high affinity receptor for immunoglobulin E
INVENTOR: Jean-Pierre Kinet, Bethesda, MD
Marie-Helene Jouvin, Bethesda, MD
ASSIGNEE: The United States of America as represented by the Department of Health and Human Services, Washington, DC (U.S. govt.)
APPL-NO: 08/201,879
DATE FILED: Feb. 24, 1994
ART-UNIT: 182
PRIM-EXMR: John Ulm
LEGAL-REP: Klarquist Sparkman Campbell Leigh & Whinston, LLP

US PAT NO: 5,807,988 [IMAGE AVAILABLE] L10: 17 of 41

ABSTRACT:
The present invention relates to nucleic acid sequences, encoding amino acid sequences of the .beta., and subunit of the human high affinity receptor for immunoglobulin E, and for amino acid sequences of the subunit. A segment of the amino acid sequence containing an antigen recognition activation motif (ARAM) that exhibits different functions than other ARAMS, including that of the ARAM-.gamma. subunit of **Fc.epsilon.RI**. The invention further relates to a method of producing the receptor by expressing cDNA for its a, .beta., and .gamma. subunits in a host cell simultaneously. Aspects of the invention are methods and compositions to inhibit the function of the human beta subunit, thereby treating or preventing allergic reactions.

US PAT NO: 5,780,597 [IMAGE AVAILABLE] L10: 18 of 41
DATE ISSUED: Jul. 14, 1998
TITLE: Monoclonal antibodies to cytotoxic lymphocyte maturation factor
INVENTOR: Maurice Kent Gately, Montville, NJ
Ulrich Andreas Gubler, Glen Ridge, NJ
Jeffrey David Hulmes, Ringwood, NJ
Frank John Podlaski, New City, NY
Alvin Seth Stern, Passaic Park, NJ
Richard Anthony Chizzonite, South Kent, CT
Yu-Ching Eugene Pan, Pine Brook, NJ
ASSIGNEE: Hoffmann-La Roche Inc., Nutley, NJ (U.S. corp.)
APPL-NO: 08/460,061
DATE FILED: Jun. 2, 1995
ART-UNIT: 186
PRIM-EXMR: Thomas M. Cunningham
ASST-EXMR: Martha T. Lubet
LEGAL-REP: George W. Johnston, William H. Epstein, Briana C. Buchholz

US PAT NO: 5,780,597 [IMAGE AVAILABLE] L10: 18 of 41

ABSTRACT:
The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.

US PAT NO: 5,770,396 [IMAGE AVAILABLE] L10: 19 of 41
DATE ISSUED: Jun. 23, 1998
TITLE: Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
INVENTOR: Jean Pierre Kinet, Bethesda, MD
ASSIGNEE: The United States of America as represented by the Department of Health and Human Services, Washington, DC (U.S. govt.)
APPL-NO: 07/869,933
DATE FILED: Apr. 16, 1992
ART-UNIT: 182
PRIM-EXMR: John Ulm
LEGAL-REP: Klarquist Sparkman Campbell Leigh & Whinston, LLP

US PAT NO: 5,770,396 [IMAGE AVAILABLE] L10: 19 of 41

ABSTRACT:
The present invention relates to nucleic acid sequences, encoding amino acid sequences of the .alpha., .beta., and .gamma. subunits of the high affinity receptor for immunoglobulin E, and for amino acid sequences of the subunits. The invention further relates to a method of producing the receptor by expressing cDNA for its .alpha., .beta., and .gamma. subunits in a host cell simultaneously. Aspects of the invention are methods and compositions to inhibit the function of the human beta subunit, thereby treating or preventing allergic reactions.

US PAT NO: 5,714,338 [IMAGE AVAILABLE] L10: 20 of 41
DATE ISSUED: Feb. 3, 1998
TITLE: Methods for diagnosis of allergy
INVENTOR: David Tai Wai Fei, Belmont, CA
John Lowe, Daly City, CA
Paula Jardieu, San Francisco, CA
ASSIGNEE: Genentech, Inc., South San Francisco, CA (U.S. corp.)
APPL-NO: 08/393,014
DATE FILED: Feb. 27, 1995
ART-UNIT: 186
PRIM-EXMR: Christina Y. Chan
ASST-EXMR: F. Pierre VanderVegt
LEGAL-REP: Richard B. Love

US PAT NO: 5,714,338 [IMAGE AVAILABLE] L10: 20 of 41

ABSTRACT:

Provided are methods for the diagnosis of allergic disease wherein IgE specific for an allergen of interest is detected in a patient serum sample by using the patient serum sample to sensitize in the presence or absence of an IgE antagonist a mast cell or basophil host genetically engineered to display surface expression of a **Fc.epsilon.RI** subunit that is capable of mediating the host cells release of a pharmacological mediator upon induction with patient serum and allergen, challenging the sensitized host cells with the allergen of interest, and determining the presence or absence of IgE specific to the allergen of interest in the patient serum sample by comparing the release of the pharmacological mediator produced by host cells sensitized with patient serum in the presence of the IgE antagonist to the release of the pharmacological mediator produced by host cells sensitized with patient serum in the absence of the IgE antagonist.

US PAT NO: 5,686,592 [IMAGE AVAILABLE] L10: 21 of 41
DATE ISSUED: Nov. 11, 1997
TITLE: High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
INVENTOR: Torsten Walter Wiegand, Boulder, CO
Diane Tasset, Boulder, CO
Larry Gold, Boulder, CO
ASSIGNEE: NeXstar Pharmaceuticals, Inc., Boulder, CO (U.S. corp.)
APPL-NO: 08/471,985
DATE FILED: Jun. 6, 1995
ART-UNIT: 187
PRIM-EXMR: Stephanie W. Zitomer
LEGAL-REP: Swanson & Bratschun LLC

US PAT NO: 5,686,592 [IMAGE AVAILABLE] L10: 21 of 41

ABSTRACT:
This invention discloses high-affinity oligonucleotide ligands to human

Immunoglobulin E (IgE), specifically RNA and ssDNA ligands having the ability to bind to IgE, and the methods for obtaining such ligands. The ligands are capable of inhibiting the interaction of IgE with its receptor.

US PAT NO: 5,670,626 [IMAGE AVAILABLE] L10: 22 of 41
DATE ISSUED: Sep. 23, 1997
TITLE: Allergen-specific human IgA monoclonal antibodies for mucosal administration
INVENTOR: Tse Wen Chang, Houston, TX
ASSIGNEE: Tanox Biosystems, Inc., Houston, TX (U.S. corp.)
APPL-NO: 08/263,258
DATE FILED: Jun. 21, 1994
ART-UNIT: 186
PRIM-EXMR: Toni R. Scheiner
LEGAL-REP: Eric P. Mirabel

US PAT NO: 5,670,626 [IMAGE AVAILABLE] L10: 22 of 41

ABSTRACT:
Disclosed are pharmaceutical preparations containing human monoclonal IgA antibodies specific for major allergenic proteins found in ragweed, house dust mites, and cat and dog dander. Also disclosed are constructs comprising physiological compatible polymer backbones or microbeads and a plurality of covalently conjugated allergen-specific binding molecules. Such binding molecules are IgG or IgA, or their F(ab').sub.2, Fab, or Fv fragments, specific to the major allergenic proteins mentioned above. Also disclosed are methods for treating a patient with allergic rhinitis, asthma, or conjunctivitis by applying a pharmaceutical preparation containing the antibodies specific for the allergenic molecules, to which the patient is sensitized, to the patient's affected mucosal tissues, such as the nasal linings, the respiratory tract, or the eyes.

US PAT NO: 5,656,273 [IMAGE AVAILABLE] L10: 23 of 41
DATE ISSUED: Aug. 12, 1997
TITLE: Method of treatment of parasitic infection using IgE antagonists
INVENTOR: Payman Amiri, San Francisco, CA
Mary Haak-Frendscho, Fitchburg, WI
Paula M. Jardieu, Berkeley, CA
ASSIGNEE: Genentech, Inc., South San Francisco, CA (U.S. corp.)
APPL-NO: 08/422,748
DATE FILED: Apr. 14, 1995
ART-UNIT: 186
PRIM-EXMR: Toni R. Scheiner
LEGAL-REP: Renee A. Fitts, Robin L. Teskin, Craig G. Svoboda

US PAT NO: 5,656,273 [IMAGE AVAILABLE] L10: 23 of 41

ABSTRACT:
This invention concerns a method for the prevention and treatment of parasitic infection by administering an IgE antagonists. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.

US PAT NO: 5,641,875 [IMAGE AVAILABLE] L10: 24 of 41
DATE ISSUED: Jun. 24, 1997
TITLE: DNA encoding chimeric IgG Fc receptor
INVENTOR: Alan D. Schreiber, Philadelphia, PA
Jong-Gu Park, Drexel Hill, PA
ASSIGNEE: University of Pennsylvania, Philadelphia, PA (U.S. corp.)
APPL-NO: 08/273,845
DATE FILED: Jul. 12, 1994
ART-UNIT: 182
PRIM-EXMR: John Ulm
LEGAL-REP: Nixon & Vanderhye P.C.

US PAT NO: 5,641,875 [IMAGE AVAILABLE] L10: 24 of 41

ABSTRACT:
The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.

US PAT NO: 5,641,863 [IMAGE AVAILABLE] L10: 25 of 41
DATE ISSUED: Jun. 24, 1997
TITLE: Chimeric IgG Fc receptors
INVENTOR: Alan D. Schreiber, Philadelphia, PA
Jong-Gu Park, Drexel Hill, PA
ASSIGNEE: University of Pennsylvania, Philadelphia, PA (U.S. corp.)
APPL-NO: 08/273,846
DATE FILED: Jul. 12, 1994
ART-UNIT: 182
PRIM-EXMR: John Ulm
LEGAL-REP: Nixon & Vanderhye P.C.

US PAT NO: 5,641,863 [IMAGE AVAILABLE] L10: 25 of 41

ABSTRACT:
The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.

US PAT NO: 5,639,947 [IMAGE AVAILABLE] L10: 26 of 41
DATE ISSUED: Jun. 17, 1997
TITLE: Compositions containing glycopolypeptide multimers and methods of making same in plants
INVENTOR: Andrew C. Hiatt, San Diego, CA
Mich B. Hein, Fallbrook, CA
ASSIGNEE: The Scripps Research Institute, La Jolla, CA (U.S. corp.)
APPL-NO: 07/971,951
DATE FILED: Nov. 5, 1992
ART-UNIT: 183
PRIM-EXMR: Patricia R. Moody
LEGAL-REP: April C. Logan

US PAT NO: 5,639,947 [IMAGE AVAILABLE] L10: 26 of 41

ABSTRACT:
The present invention contemplates a transgenic plant having somatic and germ cells containing at least two mammalian genes coding for polypeptides capable of autogenously associating with each other to form a biologically active multimer. In addition, the invention describes a method for producing a glycopolypeptide multimer by introducing first and second mammalian genes encoding the constituent parts of the multimer into first and second respective members of a plant species, generating a progeny from the first and second plant species members, and isolating the glycopolypeptide multimer from the progeny plant.

US PAT NO: 5,637,463 [IMAGE AVAILABLE] L10: 27 of 41
DATE ISSUED: Jun. 10, 1997
TITLE: Method to detect protein-protein interactions
INVENTOR: Stephen Dalton, Bloomfield, NJ
Jarema P. Kochan, Verona, NJ
Mark A. Osborne, South Brunswick, NJ
ASSIGNEE: Hoffmann-La Roche Inc., Nutley, NJ (U.S. corp.)
APPL-NO: 08/434,730
DATE FILED: May 4, 1995
ART-UNIT: 185
PRIM-EXMR: James Ketter
ASST-EXMR: John S. Brusca
LEGAL-REP: George W. Johnston, Patricia S. Rocha-Tramaloni, Raina Semionow

US PAT NO: 5,637,463 [IMAGE AVAILABLE] L10: 27 of 41

ABSTRACT:
Methods are provided for studying protein-protein interactions which require posttranslational modification of one of the proteins. The interaction is detected by reconstituting the activity of a transcriptional activator. This activity is dependent on the interactions between three different proteins. These include two chimeric proteins, one of which must be posttranslationally modified by the activity of the third protein in order for the chimeric proteins to interact. One of the chimeric proteins contains a transcriptional activation domain fused to a test protein. The second chimeric protein contains a DNA-binding domain of a transcriptional activator fused to the other test protein.

US PAT NO: 5,629,155 [IMAGE AVAILABLE] L10: 28 of 41
DATE ISSUED: May 13, 1997
TITLE: High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
INVENTOR: Torsten W. Wiegand, Boulder, CO
Diane Tasset, Boulder, CO
Larry Gold, Boulder, CO
ASSIGNEE: NeXstar Pharmaceuticals, Inc., Boulder, CO (U.S. corp.)
APPL-NO: 08/317,403
DATE FILED: Oct. 3, 1994
ART-UNIT: 187
PRIM-EXMR: Stephanie W. Zitomer
LEGAL-REP: Swanson & Bratschun, L.L.C.

US PAT NO: 5,629,155 [IMAGE AVAILABLE] L10: 28 of 41

ABSTRACT:
This invention discloses high-affinity oligonucleotide ligands to human immunoglobulin E (IgE), specifically RNA ligands having the ability to bind to IgE, and the methods for obtaining such ligands. The ligands are capable of inhibiting the interaction of IgE with its receptor.

US PAT NO: 5,591,823 [IMAGE AVAILABLE] L10: 29 of 41
DATE ISSUED: Jan. 7, 1997
TITLE: Expression of specific immunogens using viral antigens
INVENTOR: Paul P. Hung, Bryn Mawr, PA
Shaw-Guang L. Lee, Villanova, PA
Narender K. Kalyan, Wayne, PA
ASSIGNEE: American Home Products Corporation, Madison, NJ (U.S. corp.)
APPL-NO: 08/169,813
DATE FILED: Dec. 17, 1993
ART-UNIT: 183
PRIM-EXMR: Lynette F. Smith
LEGAL-REP: Richard K. Jackson

US PAT NO: 5,591,823 [IMAGE AVAILABLE] L10: 29 of 41

ABSTRACT:
Chimeric DNA fragments are provided which include a nucleotide sequence substantially the same as that which codes for the HA surface protein of an influenza A virus having five immunodominant antigenic sites, wherein a nucleotide sequence substantially the same as that which codes for a foreign epitope is inserted into the nucleotide sequence of an antigenic site. Corresponding chimeric peptides, expression vectors, and transformed hosts are provided as well. These peptides are useful in providing vaccines against the respective antigens and in test kits to detect the exposure to such antigens. Additionally, these peptides or their corresponding antibodies are useful in methods of treatment and prevention of the manifestations of exposure to these antigens, including immunotherapy.

US PAT NO: 5,587,459 [IMAGE AVAILABLE] L10: 30 of 41
DATE ISSUED: Dec. 24, 1996
TITLE: Immunoconjugates comprising tyrosine kinase inhibitors
INVENTOR: Fatih M. Uckun, White Bear Lake, MN
ASSIGNEE: Regents of the University of Minnesota, Minneapolis, MN (U.S. corp.)
APPL-NO: 08/293,731
DATE FILED: Aug. 19, 1994

ART-UNIT: 186
PRIM-EXMR: Lila Feisee
LEGAL-REP: Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A.

US PAT NO: 5,587,459 [IMAGE AVAILABLE] L10: 30 of 41

ABSTRACT:
Immunoconjugates effective for treating cancers and autoimmune diseases in humans are provided which comprise a tyrosine kinase inhibitor linked to a ligand targeting a cell surface receptor which are specifically capable of inhibiting receptor associated tyrosine kinases.

US PAT NO: 5,543,144 [IMAGE AVAILABLE] L10: 31 of 41
DATE ISSUED: Aug. 6, 1996
TITLE: Treating hypersensitivities with anti-IGE monoclonal antibodies which bind to IGE-expressing B cells but not basophils
INVENTOR: Tse W. Chang, Houston, TX
ASSIGNEE: Tanox Biosystems, Inc., Houston, TX (U.S. corp.)
APPL-NO: 08/007,180
[redacted]TE FILED: Jan. 21, 1993
[redacted]T-UNIT: 186
PRIM-EXMR: Paula K. Hutzell
LEGAL-REP: Eric P. Mirabel

US PAT NO: 5,543,144 [IMAGE AVAILABLE] L10: 31 of 41

ABSTRACT:
The invention relates to methods of treating allergic reactions and of reducing circulating IgE using antibodies which bind to secreted IgE and membrane-bound IgE on the surface of IgE-producing B cells but not to IgE on basophils or mast cells.

US PAT NO: 5,519,163 [IMAGE AVAILABLE] L10: 32 of 41
DATE ISSUED: May 21, 1996
TITLE: Inhibitors of phosphoinositide-specific phospholipase C
INVENTOR: Jackson B. Gibbs, Chalfont, PA
Kenneth S. Koblan, Chalfont, PA
Angus M. MacLeod, Bishops Stortford, United Kingdom
Kevin J. Merchant, Bishops Stortford, United Kingdom
ASSIGNEE: Merck & Co., Inc., Rahway, NJ (U.S. corp.)
APPL-NO: 08/138,133
DATE FILED: Oct. 15, 1993
ART-UNIT: 124
PRIM-EXMR: Jose G. Dees
ASST-EXMR: Barbara S. Frazier
LEGAL-REP: David A. Muthard, Mark R. Daniel

[redacted]PAT NO: 5,519,163 [IMAGE AVAILABLE] L10: 32 of 41

ABSTRACT:
Novel .alpha.-hydroxyphosphonate compounds which inhibit mammalian phosphoinositide-specific phospholipase-C. The compounds are potent anti-inflammatory and analgesic agents and may be useful for the treatment of cancer.

US PAT NO: 5,428,133 [IMAGE AVAILABLE] L10: 33 of 41
DATE ISSUED: Jun. 27, 1995
TITLE: Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
INVENTOR: Tse-wen Chang, Houston, TX
ASSIGNEE: Tanox Biosystems, Inc., Houston, TX (U.S. corp.)
APPL-NO: 07/809,034
DATE FILED: Dec. 11, 1991
ART-UNIT: 186
PRIM-EXMR: Paula Hutzell
LEGAL-REP: Eric P. Mirabel, Giulio A. DeConti

US PAT NO: 5,428,133 [IMAGE AVAILABLE] L10: 33 of 41

ABSTRACT:
Chimeric antibodies which bind to unique antigenic epitopes of IgE (designated ige.b1) which are present on IgE-bearing B lymphocytes but not basophils are described.

US PAT NO: 5,418,147 [IMAGE AVAILABLE] L10: 34 of 41
DATE ISSUED: May 23, 1995
TITLE: Glycosyl-phosphatidylinositol-specific phospholipase D
INVENTOR: Kuo-Sen Huang, Livingston, NJ
Jarema P. Kochan, Verona, NJ
Shirley H. Li, Glen Ridge, NJ
Yu-Ching E. Pan, Pine Brook, NJ
Bernard J. Scallon, Frazer, PA
Thomas C. H. Tsang, Belleville, NJ
ASSIGNEE: Hoffmann-La Roche Inc., Nutley, NJ (U.S. corp.)
APPL-NO: 07/860,825
DATE FILED: Mar. 31, 1992
ART-UNIT: 184
PRIM-EXMR: Robert A. Wax
ASST-EXMR: Keith D. Hendricks
LEGAL-REP: George M. Gould, William H. Epstein, Catherine R. Roseman

US PAT NO: 5,418,147 [IMAGE AVAILABLE] L10: 34 of 41

ABSTRACT:
The present invention involves the protein glycosyl-phosphatidyl-specific phospholipase D (GPI-PLD) in a substantially pure form, an isolated nucleotide sequence encoding GPI-PLD, vectors containing the isolated nucleotide sequence encoding GPI-PLD, and cells transformed by a vector containing the isolated nucleotide sequence encoding GPI-PLD, also nucleotide sequences, vectors and cells comprising hybrid genes with GPI-PLD, and methods for producing secreted proteins.

US PAT NO: 5,359,046 [IMAGE AVAILABLE] L10: 35 of 41
DATE ISSUED: Oct. 25, 1994
TITLE: Chimeric chains for receptor-associated signal transduction pathways
INVENTOR: Daniel J. Capon, Hillsborough, CA
Arthur Weiss, Mill Valley, CA
Brian A. Irving, San Francisco, CA
Margo R. Roberts, San Francisco, CA
Krisztina Zsebo, Woodside, CA
ASSIGNEE: Cell Genesys, Inc., Foster City, CA (U.S. corp.)
The Regents of the University of California, Oakland, CA (U.S. corp.)
APPL-NO: 07/988,194
DATE FILED: Dec. 9, 1992
ART-UNIT: 182
PRIM-EXMR: Robert J. Hill, Jr.
ASST-EXMR: Gian P. Wang
LEGAL-REP: Bertram I. Rowland

US PAT NO: 5,359,046 [IMAGE AVAILABLE] L10: 35 of 41

ABSTRACT:
Chimeric proteins and DNA sequence encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA sequences may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.

US PAT NO: 5,202,422 [IMAGE AVAILABLE] L10: 36 of 41
DATE ISSUED: Apr. 13, 1993
TITLE: Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
INVENTOR: Andrew C. Hiatt, San Diego, CA
Mich B. Hein, Fallbrook, CA
ASSIGNEE: The Scripps Research Institute, La Jolla, CA (U.S. corp.)
APPL-NO: 07/591,823
DATE FILED: Oct. 2, 1990
ART-UNIT: 186
PRIM-EXMR: David L. Lacey
ASST-EXMR: Robert D. Budens
LEGAL-REP: Douglas A. Bingham, Thomas Fitting, April C. Logan

US PAT NO: 5,202,422 [IMAGE AVAILABLE] L10: 36 of 41

ABSTRACT:
The present invention contemplates glycopolypeptide multimers having a polypeptide that contain an immunoglobulin amino acid residue sequence and an oligosaccharide that comprises a core pentasaccharide and N-acetylglucosamine-containing outer branches, such that the multimer is free from sialic acid. The production of passive immunity in an animal by administering a sialic acid free glycopolypeptide multimer is also contemplated. In addition, the invention describes a method for producing a glycopolypeptide multimer by introducing first and second mammalian genes encoding the constituent parts of the multimer into first and second respective members of a plant species, generating a progeny from the first and second plant species members, and isolating the glycopolypeptide multimer from the progeny plant.

JP410099081A L10: 37 of 41

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain the subject new DNA having a specific base sequence, containing a domain to conduct the transcription control of a human high- affinity IgE receptor α-strand gene, and capable of efficiently producing a high- affinity IgE receptor to start I-type allergic reaction.

SOLUTION: This new DNA contains a base sequence of the formula and also contains a domain to conduct the transcription control of a human high-affinity IgE receptor(Fc ε RI) α-strand gene. This DNA is expressed on the cell membrane of a mast cell or basophilic cell, being capable of efficiently producing a high-affinity IgE receptor(Fc ε RI) to start I-type allergic reaction along with being capable of controlling, as a promoter, the expression of a foreign protein gene. This DNA is obtained by conducting a PCR of a human chromosome DNA as template purified from human peripheral blood by the use, as primer, of e.g. a synthetic oligonucleotide prepared from the 5' terminal side base sequence of a human high-affinity IgE receptor cDNA.

COPYRIGHT: (C)1998,JPO

US005807988A L10: 38 of 41

ABSTRACT:

The present invention relates to nucleic acid sequences, encoding amino acid sequences of the beta , and subunit of the human high affinity receptor for immunoglobulin E, and for amino acid sequences of the subunit. A segment of the amino acid sequence containing an antigen recognition activation motif (ARAM) that exhibits different functions than other ARAMS, including that of the ARAM- gamma subunit of **Fc epsilon RI**. The invention further relates to a method of producing the receptor by expressing cDNA for its a, beta , and gamma subunits in a host cell simultaneously. Aspects of the invention are methods and compositions to inhibit the function of the human beta subunit, thereby treating or preventing allergic reactions.

WO009825647A1 L10: 39 of 41

ABSTRACT:

09/090,375

Calcium-independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the Fc gamma RIII and **Fc epsilon RI** receptors, is described, as well as methods of inhibiting allergic processes.

WO009804718A1 L10: 40 of 41

ABSTRACT:

Fusion polypeptides and salts thereof comprising at least one IgE-binding domain fused to at least one human serum albumin component, optionally via a peptide linker, and in particular, dimeric fusion polypeptides comprising HSA protein fused, at each of its amino and carboxy termini, to an extracellular domain of the alpha -chain of the human high affinity receptor for IgE (**Fc epsilon RI** alpha); process for the preparation thereof, functionally equivalent polypeptides which are intermediates in their preparation, and polynucleotide and oligonucleotide intermediates and vectors therefor. They are indicated for use in the prevention and/or treatment of IgE-mediated allergic [redacted]eases and related disorders such as atopic dermatitis, atopic asthma [redacted]chronic urticaria.

WO009722364A1 L10: 41 of 41

ABSTRACT:

<CHG DATE=19970826 STATUS=O>The present invention generally relates to a
new approach for thetherapy of allergic responses, based on targeted elimination of cells expressing the **Fc epsilon RI** receptor by a chimeric cytotoxin Fc2'-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40 - a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in E. coli, specifically and efficiently kills mouse mast cell lines expressing the **Fc epsilon RI** receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of **Fc epsilon RI** expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for **Fc epsilon RI** expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of Pseudomonas aeruginosa. The present invention also relates to a method for the preparation of said protein. This chimeric protein is prepared by genetically fusing the Fc region of the mouse IgE molecule to PE40, a truncated form of PE lacking the cell binding domain. The present [redacted]ention also provides pharmaceutical compositions, for the treatment of [redacted]gic diseases and for the treatment of hyperplasias and malignancies, [redacted]prising as an active ingredient the above mentioned chimeric protein and a conventional adjuvant product.

=> e caplan, michael/in

E#	FILE	FREQUENCY	TERM
E1	EPO	1	CAPLAN MALCOLM/IN
E2	EPO	1	CAPLAN MARK A/IN
E3		1 -->	CAPLAN MICHAEL/IN
	JPO	0	CAPLAN MICHAEL/IN
	EPO	1	CAPLAN MICHAEL/IN
E4	EPO	2	CAPLAN S/IN
E5	EPO	5	CAPLAN SANDOR/IN
E6	EPO	2	CAPLAN SERGIO D/IN
E7	EPO	1	CAPLAN SIDNEY W/IN
E8	EPO	1	CAPLAN STANLEY J/IN
E9	EPO	1	CAPLAN STANLEY Z/IN
E10	EPO	1	CAPLAN WILLIAM D/IN
E11	USPAT	1	CAPLAN, MALCOLM/IN
E12	USPAT	1	CAPLAN, MARK A/IN

=> s e3

FILE 'USPAT'
L11 0 "CAPLAN MICHAEL"/IN

FILE 'USOCR'
L12 0 "CAPLAN MICHAEL"/IN

FILE 'JPO'
L13 0 "CAPLAN MICHAEL"/IN

FILE 'EPO'
L14 1 "CAPLAN MICHAEL"/IN

TOTAL FOR ALL FILES
L15 1 "CAPLAN MICHAEL"/IN

=> d l15 cit ab

1. GB002222076A , Feb. 28, 1990, Curtains; CAPLAN, MICHAEL, et al.,
INT-CL: A47H23/05
EUR-CL: A47F3/04

GB002222076A L15: 1 of 1

ABSTRACT:

An open-fronted refrigerated display case or cabinet has its open front closed by an energy-saving slatted curtain comprising a support rail releasably secured to the top of the front of the case or cabinet and a plurality of slats weighted at their bottoms and having a quick-release connection with the support rail. <IMAGE>

=> e sosin, howard/in

E#	FILE	FREQUENCY	TERM
E1	USPAT	1	SOSIN, FRANK H/IN
E2	USPAT	1	SOSIN, GERSHON J/IN
E3		0 -->	SOSIN, HOWARD/IN
	USPAT	0	SOSIN, HOWARD/IN
	USOCR	0	SOSIN, HOWARD/IN
E4	USPAT	7	SOSIN, LAURENT/IN
E5	EPO	1	SOSINSKI C/IN
E6	EPO	6	SOSINSKI CHARLES W/IN
E7		9	SOSINSKI GREGORY C/IN
	JPO	4	SOSINSKI GREGORY C/IN
	EPO	5	SOSINSKI GREGORY C/IN

=> d his

(FILE 'USPAT' ENTERED AT 10:59:43 ON 30 MAR 1999)
SET PLURALS ON PERM

FILE 'USPAT, USOCR, JPO, EPO' ENTERED AT 11:00:12 ON 30 MAR 1999
FILE 'USPAT'
L1 1 S FC.EPSILON.(3A)HIGH(W)AFFINITY
FILE 'USOCR'
L2 0 S FC.EPSILON.(3A)HIGH(W)AFFINITY
FILE 'JPO'
L3 0 S FC.EPSILON.(3A)HIGH(W)AFFINITY
FILE 'EPO'
L4 0 S FC.EPSILON.(3A)HIGH(W)AFFINITY
TOTAL FOR ALL FILES
L5 1 S FC.EPSILON.(3A)HIGH(W)AFFINITY
FILE 'USPAT'
L6 36 S FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI
FILE 'USOCR'
L7 0 S FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI
FILE 'JPO'
L8 1 S FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI
FILE 'EPO'
L9 4 S FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI
TOTAL FOR ALL FILES
L10 41 S FC.EPSILON.(3A)HIGH(W)AFFINITY OR FC.EPSILON.RI
E CAPLAN, MICHAEL/IN
FILE 'USPAT'
L11 0 S E3
FILE 'USOCR'
L12 0 S E3
FILE 'JPO'
L13 0 S E3
FILE 'EPO'
L14 1 S E3
TOTAL FOR ALL FILES
L15 1 S E3
E SOSIN, HOWARD/IN

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

U.S. Patent & Trademark Office LOGOFF AT 11:21:40 ON 30 MAR 1999